{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:24:31Z","timestamp":1793521471005,"version":"4.5.0"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.euo.2025.03.007","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T05:13:41Z","timestamp":1744175621000},"page":"1375-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Oncological Outcomes in Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives"],"prefix":"10.1016","volume":"8","author":[{"given":"Mattia","family":"Longoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Scilipoti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Krajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u2019Andrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Del Giudice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Daniel","family":"Subiela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Afferi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Albisinni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gallioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura S.","family":"Mertens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ekaterina","family":"Laukhtina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Radziszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.03.007_b0005","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0010","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/JU.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0015","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0020","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/cncr.29071","article-title":"Quality of diagnostic staging in patients with bladder cancer: a process-outcomes link","volume":"121","author":"Chamie","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.03.007_b0025","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1001\/jama.2020.17598","article-title":"Bladder cancer: a review","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.euo.2025.03.007_b0030","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati","year":"2018","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0035","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","article-title":"Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer","volume":"118","author":"Tapiero","year":"2018","journal-title":"Urology"},{"key":"10.1016\/j.euo.2025.03.007_b0040","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0045","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-urinary Group phase III trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0050","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.03.007_b0055","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0060","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.urolonc.2021.05.015","article-title":"Non-muscle-invasive bladder cancer: an overview of potential new treatment options","volume":"39","author":"Shore","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0065","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer\u2014current and future options in the age of bacillus Calmette-Guerin shortage","volume":"21","author":"Golla","year":"2019","journal-title":"Rev Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0070","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/JU.0000000000003195","article-title":"Safety, tolerability, and preliminary efficacy of TAR-200 in patients with muscle-invasive bladder cancer who refused or were unfit for curative-intent therapy: a phase 1 study","volume":"209","author":"Tyson","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0075","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3233\/BLC-170138","article-title":"Defining priorities to improve patient experience in non-muscle invasive bladder cancer","volume":"4","author":"Garg","year":"2018","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.03.007_b0080","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/j.euo.2024.05.012","article-title":"Novel delivery systems and pharmacotherapeutic approaches for the treatment of non-muscle-invasive bladder cancer","volume":"7","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0085","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.euf.2018.08.010","article-title":"Unmet clinical needs and future perspectives in non-muscle-invasive bladder cancer","volume":"4","author":"Campi","year":"2018","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.03.007_b0090","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/cancers16101843","article-title":"Treatment modalities for non-muscle invasive bladder cancer: an updated review","volume":"16","author":"McNall","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.03.007_b0095","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.acuro.2020.06.011","article-title":"New immunotherapies for high-risk non-muscle invasive bladder cancer: current state and future perspectives","volume":"44","author":"G\u00f3mez del Ca\u00f1izo","year":"2020","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2025.03.007_b0100","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11864-014-0315-3","article-title":"Immune therapies in non-muscle invasive bladder cancer","volume":"16","author":"Ho","year":"2015","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0105","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/17512433.2021.1950531","article-title":"Immunotherapy of high risk non-muscle invasive bladder cancer","volume":"14","author":"Ahdoot","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.euo.2025.03.007_b0110","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.euo.2023.06.011","article-title":"Sequential intravesical gemcitabine and docetaxel is an alternative to bacillus Calmette-Gu\u00e9rin for the treatment of intermediate-risk non-muscle-invasive bladder cancer","volume":"6","author":"Tan","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0115","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.3390\/cancers16071366","article-title":"Revolutionizing treatment: breakthrough approaches for BCG-unresponsive non-muscle-invasive bladder cancer","volume":"16","author":"Jaromin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euo.2025.03.007_b0120","doi-asserted-by":"crossref","first-page":"7453","DOI":"10.1007\/s00432-023-04688-0","article-title":"Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study","volume":"149","author":"Arrabal Polo","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0125","doi-asserted-by":"crossref","first-page":"109.e1","DOI":"10.1016\/j.urolonc.2022.10.019","article-title":"Conductive hyperthermic chemotherapy versus electromotive drug administration of mitomycin C as intravesical adjuvant treatment of patients with intermediate or high-risk non-muscle invasive bladder cancer","volume":"41","author":"Melgarejo Segura","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0130","doi-asserted-by":"crossref","unstructured":"Afferi L, Gallioli A, Stracci D, et al. Lights and shadows of bacillus Calmette-Gu\u00e9rin (BCG)-exposed and BCG-unresponsive definitions: a practical overview. Eur Urol Oncol. In press. https:\/\/doi.org\/10.1016\/j.euo.2024.09.010.","DOI":"10.1016\/j.euo.2024.09.010"},{"key":"10.1016\/j.euo.2025.03.007_b0135","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1080\/03610918.2011.560732","article-title":"Confidence intervals for survival probabilities: a comparison study","volume":"40","author":"Yuan","year":"2011","journal-title":"Commun Stat Simul Comput"},{"key":"10.1016\/j.euo.2025.03.007_b0140","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S1078-1439(00)00099-5","article-title":"Bacillus Calmette-Guerin: is monthly maintenance an option for transitional cell carcinoma of the bladder?","volume":"6","author":"Flanigan","year":"2000","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0150","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cncr.23627","article-title":"Maintenance bacillus Calmette-Gu\u00e9rin in high-risk nonmuscle-invasive bladder cancer: How much is enough?","volume":"113","author":"Decobert","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.03.007_b0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eururo.2009.09.038","article-title":"Bacillus Calmette-Gu\u00e9rin is superior to a combination of epirubicin and interferon-\u03b12b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study","volume":"57","author":"Duchek","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0160","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/j.1442-2042.2010.02584.x","article-title":"Maintenance intravesical bacillus Calmette-Gu\u00e9rin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study Group","volume":"17","author":"Koga","year":"2010","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0165","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.02.040","article-title":"Maintenance therapy with 3-monthly bacillus Calmette-Gu\u00e9rin for 3 years is not superior to standard induction therapy in high-risk non-muscle-invasive urothelial bladder carcinoma: final results of randomised CUETO study 98013","volume":"68","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0170","doi-asserted-by":"crossref","first-page":"360","DOI":"10.4103\/UA.UA_137_19","article-title":"Single course of intravesical bacillus Calmette-Guerin versus single course with maintenance therapy in the management of nonmuscle invasive bladder cancer: a prospective randomized study","volume":"12","author":"Mohamed","year":"2020","journal-title":"Urol Ann"},{"key":"10.1016\/j.euo.2025.03.007_b0175","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0180","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00345-022-03928-1","article-title":"Recirculating hyperthermic intravesical chemotherapy with mitomycin C (HIVEC) versus BCG in high-risk non-muscle-invasive bladder cancer: results of the HIVEC-HR randomized clinical trial","volume":"40","author":"Guerrero-Ramos","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0185","doi-asserted-by":"crossref","DOI":"10.1177\/11795549231184682","article-title":"Evaluating the effectiveness of intravesical instillation of BCG by modified maintenance method in patients with high-risk Ta and T1 bladder cancer: a randomized clinical trial","volume":"17","author":"Shakhssalim","year":"2023","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0190","first-page":"61","article-title":"Comparative study between mitomycin C versus bacillus Calmette-Gu\u00e9rin (BCG) in high-risk non-muscle-invasive bladder cancer","volume":"91","author":"Zaza","year":"2024","journal-title":"Urol J"},{"key":"10.1016\/j.euo.2025.03.007_b0195","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2016.01.103","article-title":"Sequential bacillus Calmette-Gu\u00e9rin\/electromotive drug administration of mitomycin C as the standard intravesical regimen in high risk nonmuscle invasive bladder cancer: 2-year outcomes","volume":"195","author":"Gan","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0200","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, tolerability, and long-term clinical outcomes of an IL-15 analogue (N-803) admixed with bacillus Calmette-Gu\u00e9rin (BCG) for the treatment of bladder cancer","volume":"10","author":"Rosser","year":"2021","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.euo.2025.03.007_b0205","doi-asserted-by":"crossref","first-page":"S1701","DOI":"10.1016\/S0302-2838(24)01302-2","article-title":"First results of the phase Ib-II BladderGATE clinical trial: intravenous atezolizumab\u00a0+\u00a0intravesical bacillus Calmette-Gu\u00e9rin (BCG) upfront combination in BCG-na\u00efve high risk non-muscle invasive bladder cancer patients","volume":"85","author":"Guerrero-Ramos","year":"2024","journal-title":"Eur Urol"},{"issue":"4_suppl","key":"10.1016\/j.euo.2025.03.007_b0210","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1200\/JCO.2024.42.4_suppl.618","article-title":"Punch: Preliminary results from a phase II study of intra-arterial chemotherapy (IAC) combined with tislelizumab and bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"42","author":"Wang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0215","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.3390\/jcm10215105","article-title":"Long-term experience with hyperthermic chemotherapy (HIVEC) using mitomycin-c in patients with non-muscle invasive bladder cancer in Spain","volume":"10","author":"Plata","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.euo.2025.03.007_b0220","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/JU.0000000000003977","article-title":"A phase 2 trial of intravesical gemcitabine and docetaxel in the treatment of bacillus Calmette-Gu\u00e9rinNa\u00efve nonmuscle-invasive urothelial carcinoma of the bladder","volume":"212","author":"Patel","year":"2024","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0225","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.euf.2023.11.007","article-title":"Quinolone prophylaxis in conjunction with bacillus Calmette-Gu\u00e9rin instillations for bladder cancer: time to reconsider the evidence and open the quinolone box?","volume":"10","author":"Liedberg","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.03.007_b0230","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.euo.2024.06.005","article-title":"The role of mitomycin C in intermediate-risk non-muscle-invasive bladder cancer: a systematic review and meta-analysis","volume":"7","author":"Scilipoti","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0235","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.acuro.2024.01.008","article-title":"Multidisciplinary consensus document on the current treatment of bacille Calmette-Gu\u00e9rin-unresponsive non-muscle invasive bladder tumor","volume":"48","author":"Guerrero-Ramos","year":"2024","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2025.03.007_b0240","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.acuro.2024.06.004","article-title":"Consensus document on the implications of standardization of BCG supply in the management of patients with non-muscle-invasive bladder cancer","volume":"48","author":"Rodr\u00edguez Faba","year":"2024","journal-title":"Actas Urol Esp"},{"key":"10.1016\/j.euo.2025.03.007_b0245","article-title":"Intravesical electromotive drug administration for non\u2010muscle invasive bladder cancer","volume":"9","author":"Jung","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2025.03.007_b0250","doi-asserted-by":"crossref","first-page":"13769","DOI":"10.1111\/cts.13769","article-title":"Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors","volume":"17","author":"Yu","year":"2024","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.euo.2025.03.007_b0255","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5301\/uro.5000197","article-title":"Radiofrequency-induced thermo-chemotherapy effect (RITE) for non muscle invasive bladder cancer treatment: current role and perspectives","volume":"83","author":"Colombo","year":"2016","journal-title":"Urologia"},{"key":"10.1016\/j.euo.2025.03.007_b0260","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.euf.2023.06.006","article-title":"Background and update for ECOG-ACRIN EA8212: a randomized phase 3 trial of intravesical bacillus Calmette-Gu\u00e9rin (BCG) versus intravesical docetaxel and gemcitabine treatment in BCG-na\u00efve high-grade non-muscle-invasive bladder cancer (BRIDGE)","volume":"9","author":"Kates","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.03.007_b0265","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000502425","article-title":"Jahrestagung der Deutschen, \u00d6sterreichischen und Schweizerischen Gesellschaften f\u00fcr H\u00e4matologie und Medizinische Onkologie, Berlin, 11\u201314. Oktober 2019: Abstracts","volume":"42","author":"Hallek","year":"2019","journal-title":"Oncol Res Treat"},{"key":"10.1016\/j.euo.2025.03.007_b0275","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4589","article-title":"ALBAN: An open label, randomized, phase III trial, evaluating efficacy of atezolizumab in addition to one year BCG (bacillus Calmette-Guerin) bladder instillation in BCG-naive patients with high-risk nonmuscle invasive bladder cancer (AFU-GETUG 37)","volume":"37","author":"Roupret","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0280","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2217\/fon-2023-0271","article-title":"CREST: Phase III study of sasanlimab and bacillus Calmette-Gu\u00e9rin for patients with bacillus Calmette-Gu\u00e9rin-na\u00efve high-risk non-muscle-invasive bladder cancer","volume":"20","author":"Steinberg","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0285","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/bju.16332","article-title":"Cost-effectiveness analysis of different treatment modalities in BCG-unresponsive NMIBC","volume":"134","author":"Rieger","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2025.03.007_b0290","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.euf.2023.12.002","article-title":"The financial burden of guideline-recommended cancer medications for metastatic urothelial carcinoma","volume":"10","author":"Contieri","year":"2024","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2025.03.007_b0295","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.03.007_b0300","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semradonc.2022.10.003","article-title":"Pushing the envelope: the role of radiation therapy in non-muscle-invasive bladder cancer","volume":"33","author":"Kombathula","year":"2023","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0305","doi-asserted-by":"crossref","first-page":"S1224","DOI":"10.1016\/j.annonc.2023.09.2825","article-title":"2407TiP SunRISe-3: TAR-200 plus cetrelimab (CET) or TAR-200 versus intravesical bacillus Calmette-Gu\u00e9rin (BCG) in patients (pts) with BCG-naive high-risk non-muscle-invasive bladder cancer (HR NMIBC)","volume":"34","author":"Necchi","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0310","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS602","article-title":"Adding mitomycin to bacillus Calmette-Gu\u00e9rin as adjuvant intravesical therapy for high-risk, nonmuscle-invasive urothelial bladder cancer (BCGMM; ANZUP 1301)","volume":"38","author":"Liow","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0315","doi-asserted-by":"crossref","unstructured":"Hayne D, Stockler MR, James Martin A, et al. TPS4617 Poster session: Adding mitomycin (MM) to bacillus Calmette-Gu\u00e9rin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC): BCGMM; ANZUP 1301. 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS4617"},{"key":"10.1016\/j.euo.2025.03.007_b0320","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3233\/BLC-220055","article-title":"Predicting recurrence and progression in patients with non-muscle-invasive bladder cancer: systematic review on the performance of risk stratification models","volume":"8","author":"Guerrero-Ramos","year":"2022","journal-title":"Bladder Cancer"},{"key":"10.1016\/j.euo.2025.03.007_b0325","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.euo.2024.01.017","article-title":"Unlocking the potential of adequate bacillus Calmette-Gu\u00e9rin immunotherapy in very-high-risk non-muscle-invasive bladder carcinoma: a multicenter analysis of oncological outcomes and risk dynamics","volume":"7","author":"Subiela","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0330","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.euo.2021.11.006","article-title":"Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Gu\u00e9rin","volume":"5","author":"Lobo","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0335","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1200\/JCO.23.00307","article-title":"Definitions, end points, and clinical trial designs for bladder cancer: recommendations from the Society for Immunotherapy of Cancer and the International Bladder Cancer Group","volume":"41","author":"Kamat","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.03.007_b0340","doi-asserted-by":"crossref","unstructured":"Scilipoti P, Moschini M, Li R, et al. The financial burden of localized and metastatic bladder cancer. Eur Urol. In press. https:\/\/doi.org\/10.1016\/j.eururo.2024.12.002.","DOI":"10.1016\/j.eururo.2024.12.002"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000811?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125000811?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T17:34:31Z","timestamp":1766511271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2588931125000811"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.007","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological Outcomes in Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}